AMD 2016: A Review of Treatment Guidelines and the Role of A -

Name: AMD 2016: A Review of Treatment Guidelines and the Role of Appropriate Therapy [WEBINAR]
Uploaded: 2016-04-30T04:00:00+00:00
Duration: 35 min 48 s
Description: Retinal disorders, including age-related macular degeneration (AMD), can result in vision loss if not treated early and—in some disorders—continuously. Sig

Media formats available:

Details

Presenters

Overview
Retinal disorders, including age-related macular degeneration (AMD), can result in vision loss if not treated early and—in some disorders—continuously. Significant challenges lie ahead in addressing these patients’ needs, as the impact to society in both direct and indirect costs cannot be overlooked and healthcare providers are being tasked with treating increasing numbers of patients. A full knowledge of the dynamics of retinal therapeutic treatment options will be beneficial for arming both specialists and general ophthalmologists who use these drugs with a more complete understanding when counseling patients and initiating treatment. It is expected that providing this education would remove a potential barrier to greater acceptance of this area of disease management. Finally, in the interest of providing more complete care to patients, arming clinicians with current insight into the management strategies for retinal therapeutics may assist in the reduction of treatment complications and further loss of vision. Target Audience This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Assess the most recent monotherapy and combination therapy clinical study evidence using available anti-VEGF therapies for common retinal diseases, including AMD.
- Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations.
- Develop plans to initiate treatment for conditions such as AMD using anti-VEGF agents as well as better understand when to change therapeutic strategies.
Accreditation
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, Retina Today and New Retina MD.
Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Grantor Statement
This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, Retina Today, New Retina MD, or Regeneron Pharmaceuticals.
It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty members have the following financial relationships with commercial interests:

Brandon Busbee, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Aerpio Therapeutics; Genentech, Inc and Valeant Pharmaceuticals International, Inc. Grant/Research Support: Aerpio Therapeutics; Genentech, Inc; Ohr Pharmaceutical, Inc.; Opthotech Corp; and Regeneron Pharmaceuticals, Inc. Stock/Shareholder: Akorn, Incorporated. Other Financial/Material Support: Akorn, Incorporated.
Justis Ehlers,MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences, Inc.; Bioptigen Inc; Carl Zeiss Meditec; Leica Microsystems; Santen Pharmaceutical Co., Ltd.; ThromboGenics NV. Grant/Research Support: Genentech, Inc; Regeneron Pharmaceuticals, Inc. and ThromboGenics NV.
Allen C. Ho, MD has had a financial agreement or affiliation during the past year with the following commercial interest(s): Advisory Board/Consultant/Speaker’s Bureau: Aerpio Therapeutics; Alcon, Inc; Allergan, Inc; Beaver-Visitic International; DigiSight Technologies Inc; Endo Optiks; Genentech, Inc; Janssen Pharmaceuticals, Inc/Johnson & Johnson; ONL Therapeutics, LLC; Ophthotech Corporation; Physician Recommended Nutriceuticals; Regeneron Pharmaceuticals, Inc; Regenix; and Second Sight. Grant/Research Support: Alcon, Inc; Allergan, Inc; Genentech, Inc; Janssen Pharmaceuticals, Inc/Johnson & Johnson; NEI/NIH; Ophthotech Corporation; Physician Recommended Nutriceuticals; Regeneron Pharmaceuticals, Inc; and Second Sight.
Darius M. Moshfeghi, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Inc.; Genentech, Inc and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Genentech, Inc and Regeneron Pharmaceuticals, Inc.
John D. Pitcher III, MD has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Inc.;

Editorial Support Disclosure
Cheryl Cavanaugh, MS, Evolve Medical Education LLC; Emily Feinman, Retina Today and New Retina MD; Michelle Dalton, Writer; and Melanie Lawler, PhD, Reviewer have no real or apparent conflicts of interest to report.
Disclaimer
Off-Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 04/30/2016
Expiration Date: 04/30/2017